Determinants of out-of-pocket pharmaceutical expenditure and access to drugs in Catalonia

Applied Economics

Volumn 39, Issue 5, 2007, Pages 541-551

  Costa Font, Joan ^a,b   Kanavos, Panos ^a   Rovira, Joan ^b  

^a LONDON SCHOOL OF ECONOMICS   (United Kingdom)

^b UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CONSUMPTION BEHAVIOR; COST-BENEFIT ANALYSIS; DRUG; ECONOMETRICS; EXPENDITURE;

CATALONIA; EURASIA; EUROPE; SOUTHERN EUROPE; SPAIN;

EID: 33947502219     PISSN: 00036846     EISSN: 14664283     Source Type: Journal    
DOI: 10.1080/00036840500438947     Document Type: Article

References (29)

1. Alan, S., Crossley, TH, Grootendorst, P. and Veall, M. (2002) The effect of drug subsidies on out-of-pocket prescription drug expenditures by seniors: Regional evidence from Canada. Journal of Health Economics, 21, pp. 805-826.
2. Barometro Sanitario (2002) Centro de Investigaciones Sociológicas, Madrid, Spain
3. Brendt, ER, Cockburn, IM, Cooks, DL, Epstein, AM and Griliches, Z. (1998) Prescription drug process for the elderly. Monthly Labour Review, 121, pp. 23-34.
4. Catalan Health Survey (1994) Enquesta de Salud de Catalunya, Barcelona
5. Consejo del Colegio de Farmacéuticos (2003) Colegio de Farmacéuticos, Madrid
6. Cossley, T., Grootendorst, P., Korkmatz, S. and Veall, MR (2000) The effects of drugs subsidies on out-of pocket prescription drug expenditures: Regional evidence from Canada
7. Costa-Font, J. and Puig, J. (2004) Regulatory ambivalence and the limitations of pharmaceutical policy in Spain
8. Coulson, E., Terza, J., Neslan, C. and Stuart, B. (1995) Estimating the moral hazard effect of supplemental medical insurance in the demand for prescription drugs by the elderly. American Economic Review, 85, pp. 122-126.
9. Dor, A. (2004) Does cost sharing affect compliance? The case of prescription drugs, Cambridge Massachusetts
10. Dranove, D. (1989) Medicaid drug formulary restrictions. Journal of Law and Economics, 32, pp. 143-162.
11. Feldstein, M. (1976) Seven Principles of Social Insurance, pp. 6-11.
12. Grossman, M. (1972) On the concept of health capital and the demand for health. The Journal of Political Economy, 80, pp. 223-255.
13. Heckman, JJ (1979) Sample selection bias as a specification error. Econometrica, 47, pp. 153-161.
14. Hellerstein, JK (1994) The demand for post-patent prescription pharmaceuticals
15. Kenkel, DS (1991) Health behaviour, health knowledge and schooling. Journal of Political Economy, 99, pp. 287-305.
16. Leibowitz, A., Manning, W. and Newhouse, JP (1985) The demand for prescription drugs as a function of cost sharing. Social Science and Medicine, 21, pp. 1063-1070.
17. Lillard, L., Rogowski, J. and Kington, R. (1999) Insurance coverage for prescription drugs. Medical Care, 37, pp. 926-936.
18. Bastida, J López and Mossialos, E. (2000) Pharmaceutical expenditure in Spain: Cost and control. International Journal of Health Services, 30, pp. 597-615.
19. Lopez, A. (1998) Unobserved heterogeneity and censoring in the demand for health care. Health Economics, 7, pp. 429-437.
20. Manning, WG, Newhouse, JP, Duan, N., Keeler, EB, Leibowitz, A. and Marquis, MS (1987) Health insurance and the demand for medical care: evidence from randomised experiment. American Economic Review, 77, pp. 251-277.
21. Mossialos, E. and Grand, J Le (1999) Cost containment in the European Union: An overview. Health Care and Cost Containment in the European Union, Ashgate, London
22. Newhouse, JP (1993) and the Insurance experiment group. Free for All? Lessons from the RAND Health Care Insurance Experiment, Harvard University Press, Cambdridge, MA
23. Pauly, MV (1974) Over insurance and the public provision of insurance: the role of moral hazard and adverse selection. Quarterly Journal of Economics, 88, pp. 44-62.
24. Pavcnik, N. (2000) Do pharmaceutical prices respond to insurance?, Cambridge Massachusetts
25. Poisal, JA, Murray, LA, Chulis, GS and Cooper, BS (1999) Prescription drug coverage and spending for Medicare beneficiaries. Health Care Finance Review, 20, pp. 15-27.
26. Puig, J. (1988) Gasto Farmaceutrico en España: Efectos de la participación en el coste. Investigaciones Economicas, 12, pp. 45-68.
27. Stuart, B., Brandt, N., Brieacher, B., Fahlam, D., Palumbo, F., Pizarro, J. and Stuart, L. (2000) Issues in prescription drug coverage, pricing, utilisation and spending: What we know and what we need to know, Washington, DC
28. Tamblyn, R., Laprise, R., Hanley, JA, Abrahamowitz, M., Scott, S., May, N., Hurley, J., Grad, R., Latimer, E., Perreault, R., McLeod, P., Huang, A., Larochelle, P. and Mallet, L. (2001) Adverse events associated with prescription drug cost-sharing among poor and elderly persons. Journal of the American Medical Association, 285, pp. 421-429.
29. Vera-Hernández, MA (1999) Duplicate coverage and the demand for health care in Catalonia. Health Economics, 8, pp. 579-598.